Welcome to our dedicated page for Pharma-Bio Serv SEC filings (Ticker: PBSV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pharma-Bio Serv, Inc. (PBSV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Pharma-Bio Serv is described in its public communications as a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm serving pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries.
Among the filings available for PBSV are current reports on Form 8-K. For example, a Form 8-K dated September 15, 2025 states that Pharma-Bio Serv issued a press release announcing its results of operations for the three and nine months ended July 31, 2025, and that the press release is furnished as an exhibit to that report. The filing also notes that the information under that item is furnished rather than filed for purposes of certain provisions of the Securities Exchange Act of 1934 and the Securities Act of 1933.
Through this page, users can monitor Pharma-Bio Serv’s SEC disclosures, including current reports that reference earnings press releases and other material events. Stock Titan enhances these filings with AI-powered summaries that explain the key points of each document in plain language, helping readers understand the significance of the information without having to parse every technical detail.
Filings are updated from the SEC’s EDGAR system, and users can review items such as Form 8-K reports that relate to results of operations and financial condition. The AI tools on this page are designed to highlight important elements within each filing so that investors and researchers can quickly grasp the main disclosures for PBSV.
Pharma-Bio Serv, Inc. (PBSV) discloses share counts, tax items, repurchases and customer concentration. The company reports 10,000,000 authorized shares with 23,519,672 issued and 22,920,442 outstanding at July 31, 2025, and notes 599,230 common shares held in treasury at that date. Under U.S. tax reforms, a 100% exemption on certain foreign-source dividends is noted while GILTI subjects foreign subsidiary earnings to a reduced U.S. tax rate of 10.5%. The Transition Tax payment period runs eight years through the companys second quarter of fiscal 2026. The Spanish subsidiary tax rate is 25%. During the period, the company repurchased 536,258 and 498,557 common shares for aggregate amounts of $507,112 and $484,871, respectively, and paid $1,719,918 on March 20, 2025. Revenue concentration from certain global affiliated groups rose to 53.8% for the nine months ended July 31, 2025, and amounts due from those affiliates represented 55.3% of total accounts receivable at July 31, 2025.